Stock screener

INAB

Conviction 20HealthcareScan · Mon, Aug 10, 2026
INAB$0.9700-0.88%
ResistanceSupportVol 14
63 bars
Vol MA14 62.78K
May 11May 28Jun 16Jul 6Jul 23Aug 10
IN8BIO, INC.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.in8bio.com
Price0.9700
Change-0.88%
Gap+0.18%
Rel volume2.31×
Avg volume61.72K
Avg $ vol69.46K
SMA 201.15
SMA 501.33
SMA 2001.67
Price vs 50-27.14%
Price vs 200-41.85%
MA stackbearish
50/200 cross
Supertrenddown · 1.18
RSI (14)26
MACD hist-0.01
MACD cross
Stoch %K / %D20 / 20
ADX (14)42
+DI / −DI9 / 34
RSI divergence
MACD divergence
ATR %+7.41%
ADR %5.73%
52w high2.59
52w low0.9600
From 52w high-62.55%
Above 52w low+1.04%
New 52w highNo
SqueezeOff
Bollinger width53.58%
%B0.21
Donchian pos12.45%
Donchian high1.46
Donchian low0.9000
AVWAP (52w high)1.61
vs AVWAP high-39.75%
AVWAP (52w low)0.9698
vs AVWAP low+0.02%
OBV trendDown
Chaikin MF (20)-0.29
Today vs 20d2.31×
Avg vol (14d)62.78K
Avg vol (20d)61.72K
Avg $ vol (20d)69.46K
Market cap9.56M
RS 3m (vs SPY)-44.53%
RS 6m (vs SPY)-62.61%
RS line new highNo
Trend template0/8
Technical rank5.3
1 week+1.04%
1 month-27.07%
3 months-38.61%
6 months-51.26%
1 year-54.88%
YTD-60.57%
P/E-0.49
P/B0.52
P/S
P/FCF
EPS-4.44
Div yield
ROE-105.87%
ROA-89.40%
Debt/Eq
Current8.21
EV/EBITDA
Gross margin
Net margin
Rev growth
EPS growth36.13%
Price target
Target upside
Analyst rating
Institutional
Ent. value-8.57M
Revenue
Net income-4.78M
Gross profit
Free cash flow
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out9.85M
Employees18
ListedFri, Jul 30, 2021
Free float6.96M
Float %70.7%
Short interest20.79K
Days to cover0.4d
Short volume45.5%
Squeeze score21 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction20 / 100
Pattern quality
Tech rank5.3 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance1.52
Support0.9200
Days since event
Candle confirm
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in INAB

All disclosures →
No recent disclosed trades by Congress in INAB. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in INAB · 8 buys · 1 sell

InsiderSideShares
FAIRBAIRN EMILY
Director · Common Stock · 2026-05-27
Gift724.64K
FAIRBAIRN EMILY
Director · Common Stock · 2026-05-27
Other
Ho William Tai-Wei
CEO · Employee Stock Option (right to buy) · 2026-05-09
Grant154.5K
FAIRBAIRN EMILY
Director · Stock Option (right to buy) · 2026-05-09
Grant22K
Epperly Corinne
Director · Stock Option (right to buy) · 2026-05-09
Grant22K
Rochlin Kate
President and COO · Employee Stock Option (right to buy) · 2026-05-09
Grant60K
Lamb Lawrence
EVP and CSO · Employee Stock Option (right to buy) · 2026-05-09
Grant54K
Graff Jeremy R.
Director · Stock Option (right to buy) · 2026-05-09
Grant22K
McCall Patrick
CHIEF FINANCIAL OFFICER · Employee Stock Option (right to buy) · 2026-05-09
Grant56.25K
Greenwood Luba
Director · Stock Option (right to buy) · 2026-05-09
Grant22K

SEC filings

EDGAR filings in INAB · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.